You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
A Framework for mHealth App Security and Privacy Analysis
SBC: UBITRIX INTERNATIONAL, INC. Topic: NLMPROJECT SUMMARY/ABSTRACT With the increased use of mobile health (mHealth) apps to improve health outcomes, protecting private health data is becoming increasingly important. These mHealth apps are offered by healthcare providers and used by patients for various reasons such as paying bills, scheduling appointments, sending messages to providers, accessing lab results, and viewing prescriptions an ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Treatment of Inflammatory Complications of Respiratory Infection
SBC: Respana Therapeutics, Inc Topic: NIAIDAbstract Respana Therapeutics is advancing a proprietary first-in-class therapeutic monoclonal antibody (mAb), RT- 002, for the treatment of debilitating and often lethal inflammatory complications associated with acute respiratory conditions. We have identified a lead candidate, RT-002, and an equally promising alternative. RT-002 targets the surfactant protein A receptor SP-R210, a host-mediated ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Real-time Multimodal Diffuse Reflectance and Polarization Imaging Based Nerve Identification in Surgical Field of View
SBC: YAYA SCIENTIFIC LLC Topic: NIBIBPROJECT SUMMARY We propose to develop a novel non-contact, label-free multimodality imager that provides real-time intraoperative identification of nerves within the surgical field-of-view to facilitate the prevention of unintended nerve damage (termed iatrogenic nerve injury) during surgical procedures, as they are a major source of postsurgical complications, e.g., chronic pain. In the United St ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
SIRPant Technology for anti-Cancer Immunity
SBC: SIRPANT IMMUNOTHERAPEUTICS INC Topic: 102PROJECT SUMMARY Immune evasion is a hallmark of cancer. Various tumor immunotherapy treatments, such as immune checkpointblockade and cancer vaccination, have been developed to overcome cancer’s ability to avoid immune detectionand destruction; however, the result of these endeavors have not been satisfactory given a number of criticalbarriers. One of these barriers, and a prominent mechanism by ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Optimizing Radiosynthetic Yield of [18F]FTT For Wide-Spread Distribution
SBC: Trevarx Biomedical, Inc. Topic: 102ABSTRACT: Poly (ADP-ribose) polymerase inhibitors (PARPi’s) have emerged as important therapeutic agents targeting a broadening class of gene mutations approved for treatment of breast, ovarian, prostate, and other cancers. Genomic assays of BRCA-related genes and tumor homologous repair deficiency are used as companion diagnostics for PARPi therapy but have imperfect predictive efficacy for PAR ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
A novel PEDF peptide mimetic for diabetic retinopathy
SBC: SKYRAN BIOLOGICS, INC. Topic: NEIAbstract The overall goal of Skyran Biologics is to develop a potent topical therapeutic for diabetic retinopathy (DR), a leading cause of vision loss globally. Our research team identified Pigment Epithelium-Derived Factor (PEDF) and showed it is expressed in the eye and provides significant protection to the injured retina. Since its discovery, we identified a 44-mer N-terminus bioactive region ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Optimizing a Stapled-Peptide That Specifically Targets HSV-1 to Treat Herpes Ocular Keratitis
SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC. Topic: NIAIDABSTRACT Infection of the eye by Herpes Simplex Virus-1 (HSV-1) can result in Herpes Keratitis (HK), which is the leading cause of infectious corneal blindness worldwide. In the U.S., nearly 500,000 individuals experience ocular herpes infections that are often recurrent and culminate in progressive corneal scarring and loss of vision. The gold standard treatment is Acyclovir (ACV) that targets HS ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Development and Evaluation of Rosette Array Technology for HumanNeurodevelopmental Toxicity Screening
SBC: Neurosetta LLC Topic: RProject Summary Pre-clinical and pre-field toxicology testing of new drugs and chemicals does not routinely include direct assessment of human developmental neurotoxicity (DNT). Current standards for DNT testing require use of animal models with limited throughput and significant differences from human central nervous system (CNS) development. As such, many chemical products have required post-app ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Rehabilitation Using Community-Based Affordable Robotic Exercise Systems (Rehab CARES)
SBC: Recupero Robotics LLC Topic: NICHDPROJECT SUMMARY Stroke is the leading cause of serious long-term disability. It is estimated that 5.8–6.5 million people currently live with stroke related disability in the US and that this number will increase by 20.5% by 2030. The current US health infrastructure is not prepared for these increasing numbers. Limitations in health insurance coverage and the shortage of rehabilitation practitio ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Adjustable prosthetic sockets for children and adolescents with lower limb loss to accommodate growth
SBC: IFIT PROSTHETICS, LLC Topic: NICHDPediatric limb loss, although relatively infrequent compared to adults, results in substantial hardship for children and their families. The principal business interest? iFIT Prosthetics, LLC®? successfully developed and manufactured innovative, fully adjustable, transtibial and transfemoral prosthetic devices, and demonstrated their safety, comfort, and functionality in adults. Made of injection ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health